These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17136230)

  • 1. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
    Rubenstein M; Tsui P; Guinan P
    Methods Find Exp Clin Pharmacol; 2006 Oct; 28(8):515-8. PubMed ID: 17136230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2007; 24(2):189-96. PubMed ID: 17848743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
    Rubenstein M; Anderson KM; Tsui P; Guinan P
    Med Hypotheses; 2006; 67(6):1375-80. PubMed ID: 16870352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.
    Rubenstein M; Guinan P
    In Vivo; 2010; 24(4):489-93. PubMed ID: 20668314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2008; 25(2):182-6. PubMed ID: 17972023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2009; 26(2):124-30. PubMed ID: 18686047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2007; 24(4):372-8. PubMed ID: 17917084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancer.
    Tsui P; Rubenstein M; Guinan P
    In Vivo; 2005; 19(4):653-6. PubMed ID: 15999529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression.
    Rubenstein M; Hollowell CM; Guinan P
    In Vivo; 2011; 25(5):725-32. PubMed ID: 21753125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol.
    Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
    Med Oncol; 2003; 20(1):29-35. PubMed ID: 12665682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice.
    Rubenstein M; Mirochnik Y; Chou P; Guinan P
    J Surg Oncol; 1996 Jul; 62(3):194-200. PubMed ID: 8667627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor.
    Rubenstein M; Glick R; Lichtor T; Mirochnik Y; Chou P; Guinan P
    Med Oncol; 2001; 18(2):121-30. PubMed ID: 11778757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
    Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
    Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):649-52. PubMed ID: 12616956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.
    Normanno N; Bianco C; Damiano V; de Angelis E; Selvam MP; Grassi M; Magliulo G; Tortora G; Bianco AR; Mendelsohn J; Salomon DS; Ciardiello F
    Clin Cancer Res; 1996 Mar; 2(3):601-9. PubMed ID: 9816209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model.
    Tsui P; Rubenstein M; Guinan P
    Med Oncol; 2004; 21(4):339-48. PubMed ID: 15579918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.
    Rubenstein M; Hollowell CM; Guinan P
    Med Oncol; 2012 Jun; 29(2):835-41. PubMed ID: 21573974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity.
    Rubenstein M; Hollowell CM; Guinan P
    In Vivo; 2011; 25(1):61-7. PubMed ID: 21282736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
    Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.